Vape-tech company Ispire Technology Inc. ISPR reported Monday financial results for the fiscal year 2023, which ended on June 30, 2023 revealing 100.4% growth in revenue from cannabis products year-over-year, reaching $40 million.  "The fiscal year 2023 marked a significant milestone for Ispire, with a 100.4% and 10.9% surge in cannabis and tobacco vaping products revenues, respectively from fiscal year 2022,” stated Michael Wang, the co-chief executive officer of Ispire. “Overall revenue increased 31.2%. This growth was predominantly driven by the doubling of the revenues from our cannabis vaping products in the United States and a rise in sales of tobacco vaping products in Europe. Central to this success is our multi-pronged strategy: expanding our e-cigarette vaporizer technology sales and innovating our cannabis vaporizer offerings for both medical and recreational sectors.” Revenue increased 31.2% to $115.6 million as compared to $88.1 million in the same period of 2022. Tobacco vaping products contributed $75.6 million and cannabis vaping products contributed $40.0 million to revenue during the fiscal year 2023; Gross profit increased 58.4% to $21.1 million as compared to $13.3 million in the same period of 2022; Gross margin increased to 18.2% as compared to 15.1% in the same period of 2022. Total operating expenses increased 79.4% to $25.6 million as compared to $14.3 million in the same period of 2022; and Net loss of $6.1 million as compared to net loss of $1.9 million in the same period of 2022. As of June 30, 2023, Ispire had cash and cash equivalents of $40.3 million and working capital of $28.8 million. Revenue for cannabis vaping products for the fiscal year of 2024 is projected at somewhere between $80 million and $90 million, representing growth between 100% and 125% from fiscal year 2023. Revenue for tobacco vaping products for the fiscal year 2024 is projected at somewhere between $95 million and $105 million, representing growth between 25% and 40% from the fiscal year 2023. Ispire shares were trading 0.31% lower at $9.70 per share during Monday’s pre-market session.  The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding. Photo: Courtesy of Jose Luis Sanchez Pereyra via Pexels  © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Sort by estimates, projected upside, profit surprises, and more to easily find new stocks to invest in or check up on your portfolio. Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about. Click on the image for more info. Want to understand what this means for the future of the industry?  Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.  Get your tickets now before prices surge by following this link.